{
    "clinical_study": {
        "@rank": "117550", 
        "acronym": "KiCK Pain", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo arm. A 5mL liquid placebo will be given three times daily for 2 weeks."
            }, 
            {
                "arm_group_label": "Ketamine 0.25 mg/kg/dose", 
                "arm_group_type": "Experimental", 
                "description": "A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks."
            }, 
            {
                "arm_group_label": "Ketamine 0.5 mg/kg/dose", 
                "arm_group_type": "Experimental", 
                "description": "A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks."
            }, 
            {
                "arm_group_label": "Ketamine 1 mg/kg/dose", 
                "arm_group_type": "Experimental", 
                "description": "A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to select the most tolerable dose of oral ketamine for children with\n      chronic pain. Children will be given either placebo or one of three dosages of oral ketamine\n      for 2 weeks. The dosage that is most tolerable will be selected for further study."
        }, 
        "brief_title": "Ketamine in Chronic Kid's PainKiCK Pain", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Pain", 
        "detailed_description": {
            "textblock": "Children with chronic pain are randomized to one of four arms (three study drug arms, one\n      placebo arm) in a randomized, double-blinded fashion. Children are treated for 2 weeks and\n      then monitored for an additional 12 weeks. Study participation is a total of 14 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject, parent, or guardian willing and able to give informed consent\n\n          -  NRS for pain over the past 24 hours >4 at baseline\n\n          -  Chronic pain, which has been present for >3 months, or persisting longer than is\n             normal for the underlying diagnosis\n\n          -  Chronic pain related to physiologic diagnoses including but not limited to: cancer,\n             rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and\n             neuromuscular disease (e.g. Duchenne muscular dystrophy)\n\n          -  Able to tolerate and cooperate with neurocognitive assessment\n\n          -  Age 8-20 years old\n\n        Exclusion Criteria:\n\n          -  If they are known or suspected to have drug addiction\n\n          -  Uncontrolled psychiatric disorder such as depression, schizophrenia, or bipolar\n             disorder\n\n          -  Uncontrolled hypertension\n\n          -  Known liver disease or elevation of AST or ALT greater than 3 times the upper limit\n             of normal.\n\n          -  Previous intolerance or allergic reaction to ketamine\n\n          -  Pregnancy\n\n          -  Use of CYP3A4 inhibitors or inducers within the 2-week period prior the study drug\n             administration or within 5 half-lives of the respective medication, whichever is\n             longer, until study conclusion.\n\n          -  Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study\n             drug administration until study conclusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "20 Years", 
            "minimum_age": "8 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755169", 
            "org_study_id": "KiCK Pain"
        }, 
        "intervention": {
            "arm_group_label": [
                "Ketamine 0.25 mg/kg/dose", 
                "Ketamine 0.5 mg/kg/dose", 
                "Ketamine 1 mg/kg/dose"
            ], 
            "description": "Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).", 
            "intervention_name": "Ketamine", 
            "intervention_type": "Drug", 
            "other_name": "Ketalar"
        }, 
        "intervention_browse": {
            "mesh_term": "Ketamine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic pain", 
            "Child", 
            "Pediatric", 
            "Ketamine"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "contact": {
                "email": "bredlau@musc.edu", 
                "last_name": "Amy-Lee Bredlau, MD", 
                "phone": "843-876-2872"
            }, 
            "facility": {
                "address": {
                    "city": "Charleston", 
                    "country": "United States", 
                    "state": "South Carolina", 
                    "zip": "29425"
                }, 
                "name": "Medical University of South Carolina"
            }, 
            "investigator": {
                "last_name": "Amy-Lee Bredlau, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Ketamine in Chronic Kid's Pain (KiCK Pain)", 
        "overall_contact": {
            "email": "bredlau@musc.edu", 
            "last_name": "Amy-Lee Bredlau, MD", 
            "phone": "843-876-2872"
        }, 
        "overall_contact_backup": {
            "email": "infingep@musc.edu", 
            "last_name": "Patricia Infinger, CCRP", 
            "phone": "(843) 792-7857"
        }, 
        "overall_official": {
            "affiliation": "Medical University of South Carolina", 
            "last_name": "Amy-Lee Bredlau, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The dosage that is best tolerated by participants will be selected as the dosage to be studied in future trials.", 
            "measure": "Dosage of ketamine that is most tolerable", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755169"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of South Carolina", 
            "investigator_full_name": "Amy-Lee Bredlau", 
            "investigator_title": "Director, Pediatric Brain Tumor Program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Medical University of South Carolina", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of South Carolina", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}